Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
4.340
-0.100 (-2.25%)
Aug 14, 2025, 11:50 AM - Market open

Monte Rosa Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Net Income
24.17-72.7-135.35-108.5-73.96-35.88
Upgrade
Depreciation & Amortization
10.6210.228.323.752.130.54
Upgrade
Loss (Gain) From Sale of Assets
-0.06--0.02-0.110.02-
Upgrade
Loss (Gain) From Sale of Investments
-3.55-2.95-3.78-1.95--
Upgrade
Stock-Based Compensation
18.9418.1316.6711.665.20.35
Upgrade
Other Operating Activities
-2.28-2.1-2.14.810.967.68
Upgrade
Change in Accounts Receivable
9.330.331.9-0.19--
Upgrade
Change in Accounts Payable
-1.056.255.76-0.74-0.713.44
Upgrade
Change in Unearned Revenue
-26.7783.3850---
Upgrade
Change in Other Net Operating Assets
-1.631.4414.81-1.26.990.82
Upgrade
Operating Cash Flow
27.7242-43.8-92.47-59.36-23.05
Upgrade
Capital Expenditures
-3.86-3.99-19.04-12.91-9.73-3.39
Upgrade
Sale of Property, Plant & Equipment
--0.060.110.08-
Upgrade
Investment in Securities
-64.19-40.46107.78-206.42--
Upgrade
Investing Cash Flow
-68.05-44.4588.8-219.22-9.65-3.39
Upgrade
Issuance of Common Stock
152.532.6121.45255.79-
Upgrade
Other Financing Activities
-46.3624.88-0.98-21.23-0.44
Upgrade
Financing Cash Flow
198.8927.4920.47377.5660.06
Upgrade
Net Cash Flow
-39.3396.4472.49-291.22308.5533.62
Upgrade
Free Cash Flow
23.8538.01-62.84-105.38-69.1-26.44
Upgrade
Free Cash Flow Margin
13.40%50.26%----
Upgrade
Free Cash Flow Per Share
0.290.51-1.22-2.23-2.76-17.43
Upgrade
Levered Free Cash Flow
40.7581.97-53.37-72.4-61.297.6
Upgrade
Unlevered Free Cash Flow
40.7581.97-53.37-72.4-61.297.6
Upgrade
Change in Working Capital
-20.1291.472.47-2.136.294.26
Upgrade
Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q